Cargando…
Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560347/ https://www.ncbi.nlm.nih.gov/pubmed/31167822 http://dx.doi.org/10.1182/bloodadvances.2019000461 |
| _version_ | 1783425952352567296 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6560347 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65603472019-06-12 Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. Blood Adv Erratum American Society of Hematology 2019-06-05 /pmc/articles/PMC6560347/ /pubmed/31167822 http://dx.doi.org/10.1182/bloodadvances.2019000461 Text en © 2019 by The American Society of Hematology |
| spellingShingle | Erratum Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. |
| title | Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. |
| title_full | Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. |
| title_fullStr | Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. |
| title_full_unstemmed | Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. |
| title_short | Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. |
| title_sort | keleku-lukwete n, suzuki m, panda h, et al. nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. blood adv. 2019;3(8):1285-1297. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560347/ https://www.ncbi.nlm.nih.gov/pubmed/31167822 http://dx.doi.org/10.1182/bloodadvances.2019000461 |